Changeflow GovPing Healthcare & Life Sciences Apotex ANDA 210456 Approved Multiple Vitamins I...
Routine Rule Added Final

Apotex ANDA 210456 Approved Multiple Vitamins Injection Pediatric

Favicon for www.accessdata.fda.gov FDA Drugs@FDA - New Applications and Actions
Published
Detected
Email

Summary

FDA approved Abbreviated New Drug Application (ANDA) 210456 for MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) submitted by Apotex. The approval covers an injectable intravenous formulation containing 13 active ingredients including ascorbic acid, various B vitamins, vitamin A, vitamin D, vitamin E, and vitamin K at specified strengths per vial. The product received TE Code AP (bioequivalence Rating AP) and carries Prescription marketing status but is not listed as a Reference Listed Drug (RLD) or Reference Standard (RS).

Published by FDA on accessdata.fda.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors FDA Drugs@FDA - New Applications and Actions for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 9 changes logged to date.

What changed

FDA granted approval to Apotex for ANDA 210456 covering Multiple Vitamins Injection Pediatric (Pharmacy Bulk Package), an injectable intravenous product containing multiple vitamins at specified concentrations per vial. The approval is classified as STANDARD review priority with no orphan drug status. The product bears TE Code AP (bioequivalence rating AP), indicating therapeutic equivalence to approved reference products.

Pharmaceutical companies, healthcare providers, and pharmacies should note this new pediatric vitamin injection is now available for prescribing and dispensing as a Prescription product. The pharmacy bulk package formulation may be relevant for institutional settings requiring multi-dose preparation. Generic competition in this therapeutic category may intensify as additional ANDA approvals follow.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

*Home | *

Abbreviated New Drug Application (ANDA): 210456
Company: APOTEX
- Email

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL INJECTABLE;INTRAVENOUS Prescription AP No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
04/21/2026 ORIG-1 Approval STANDARD Label is not available on this site.

MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE)

INJECTABLE;INTRAVENOUS; 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL
TE Code = AP

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL INJECTABLE;INTRAVENOUS Prescription No AP 210456 APOTEX

Parties

Get daily alerts for FDA Drugs@FDA - New Applications and Actions

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Published
April 21st, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Generic drug approval Pharmaceutical manufacturing IV drug distribution
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Topics
Healthcare Medical Devices

Get alerts for this source

We'll email you when FDA Drugs@FDA - New Applications and Actions publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!